PTGX - Protagonist Therapeutics, Inc.
| Previous Close | 7.25 |
| Open | 7.21 |
| Bid | 5.19 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 7.12 - 7.49 |
| 52 Week Range | 5.50 - 23.97 |
| Volume | 192,910 |
| Avg. Volume | 297,650 |
| Market Cap | 155.637M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.09 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.63 |
- PR Newswire•2 days ago
Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
NEWARK, Calif., June 18, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that results of a Phase 1 study in healthy volunteers and supportive pre-clinical data for the Company's novel injectable hepcidin mimetic, PTG-300, were the subject of oral presentations on June 16, 2018, at the 23rd Congress of the European Hematology Association (EHA) in Stockholm. Protagonist is developing PTG-300 for the treatment of anemia and iron overload in related rare blood disorder diseases, including beta thalassemia.
- PR Newswire•14 days ago
Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference
NEWARK, Calif. , June 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will provide a corporate ...
- PR Newswire•19 days ago
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, Calif., June 1, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that on May 31, 2018, it issued an inducement award to Samuel Saks, M.D., the Company's recently appointed Chief Development Officer, in accordance with the terms of Dr. Saks' employment offer letter. The award was granted under the Protagonist Therapeutics Inducement Award Plan, which was adopted May 29, 2018. The inducement award consists of an option to purchase 50,000 shares of Protagonist Therapeutics common stock and has a ten-year term.
- PR Newswire•27 days ago
Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer
NEWARK, Calif. , May 24, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the appointment of Samuel Saks , M.D., as Chief Development Officer. In this newly-created role, ...
- GlobeNewswire•29 days ago
Report: Developing Opportunities within Integer, Sykes Enterprises, Protagonist Therapeutics, Egalet, Watsco, and Extra Space Storage — Future Expectations, Projections Moving into 2018
NEW YORK, May 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Integer ...
- PR Newswire•last month
Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association
NEWARK, Calif. , May 17, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that clinical and preclinical abstracts for PTG-300, the Company's injectable hepcidin mimetic ...
- PR Newswire•last month
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
NEWARK, Calif., May 16, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced the appointment of Bryan Giraudo to its Board of Directors. Mr. Giraudo currently serves as Chief Financial Officer of Gossamer Bio and was previously Senior Managing Director at Leerink Partners. "We are excited that Bryan has chosen to join the Protagonist board.
- Associated Press•last month
Protagonist Therapeutics: 1Q Earnings Snapshot
The Newark, California-based company said it had a loss of 36 cents per share. The biopharmaceutical company posted revenue of $10.8 million in the period. Protagonist Therapeutics shares have fallen 60 ...
- PR Newswire•last month
Protagonist Therapeutics Reports First Quarter 2018 Financial Results
NEWARK, Calif. , May 9, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the first quarter ended March 31, 2018 . "Protagonist is continuing ...
- PR Newswire•2 months ago
Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference
- Selective Dual Mu/Delta Opioid Receptor Agonists are Superior to Eluxadoline in Preclinical Models of IBS-D - NEWARK, Calif. , May 3, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ...
- Zacks•2 months ago
Protagonist Therapeutics (PTGX) Enters Oversold Territory
Protagonist Therapeutics, Inc. (PTGX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
- Zacks•3 months ago
Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion
The biotech sector was in focus last week with Protagonist's stock plunging on news of discontinuation of a phase IIb study and Verona Pharma stock surging on positive top-line data from COPD study among others.
- GlobeNewswire•3 months ago
Recent Analysis Shows ICU Medical, Motorcar Parts of America, Protagonist Therapeutics, A. Schulman, PennantPark Investment, and H&E Equipment Services Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•3 months ago
Protagonist Therapeutics Stalls Ulcerative Colitis Study
Protagonist Therapeutics' (PTGX) shares plunge more than 50%, following discontinuation of a mid-stage study on its key ulcerative colitis candidate, PTG-100.
- Motley Fool•3 months ago
Why KB Home, Longfin, and Protagonist Therapeutics Slumped Today
These stocks missed the rally. Find out why.
- Motley Fool•3 months ago
Why Protagonist Therapeutics, Inc. Is Imploding Today
Traders rush for the exits after the company announces bad clinical news.
- PR Newswire•3 months ago
Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis
NEWARK, Calif., March 26, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that the Company is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC). This decision followed a planned interim analysis by an independent Data Monitoring Committee (DMC) of unblinded efficacy and safety data from the first 65 patients from the ongoing 240 patient trial who had completed the 12 week treatment with PTG-100. Based on the DMC's recommendation received after the market close on Friday, and while further review of the data is being conducted, Protagonist is notifying PROPEL trial investigators that randomization of potential participants and further treatment of patients currently in the study will be discontinued.
- PR Newswire•3 months ago
Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference
NEWARK, Calif. , March 9, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., the company's President and Chief Executive Officer, will provide ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of PTGX earnings conference call or presentation 7-Mar-18 9:30pm GMT
Q4 2017 Protagonist Therapeutics Inc Earnings Call
- Associated Press•3 months ago
Protagonist Therapeutics posts 4Q loss
On a per-share basis, the Newark, California-based company said it had a loss of 15 cents. The biopharmaceutical company posted revenue of $11.3 million in the period. For the year, the company reported ...
- PR Newswire•3 months ago
Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results
Protagonist to host conference call today at 1:30 pm PT/4:30 pm ET NEWARK, Calif. , March 7, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today reported its financial results for ...
- ACCESSWIRE•3 months ago
Protagonist Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018 at 4:30 PM Eastern ...
- Simply Wall St.•3 months ago
Analysts Expect Breakeven On The Horizon For Protagonist Therapeutics Inc (NASDAQ:PTGX)
Protagonist Therapeutics Inc’s (NASDAQ:PTGX): Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based chemical entities to address various unmet medical needs. The company’s loss has recentlyRead More...
- PR Newswire•3 months ago
FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia
NEWARK, Calif. , March 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300, ...
- PR Newswire•4 months ago
Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference
NEWARK, Calif. , March 1, 2018 Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., the company's President and Chief Executive Officer, will provide a corporate ...
